AMLX
Amylyx Pharmaceuticals, Inc.
1W: +0.3%
1M: -6.0%
3M: +10.6%
YTD: +21.1%
1Y: +265.9%
3Y: -56.5%
$13.83
+0.17 (+1.24%)
After Hours: $14.00 (+0.17, +1.23%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider+$16.2M
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.1B
52W Range3.11-17.49
Volume1,043,243
Avg Volume1,299,693
Beta-0.30
Dividend—
Analyst Ratings
Company Info
CEOJoshua Cohen
Employees123
SectorHealthcare
IndustryBiotechnology
IPO Date2022-01-07
Websiteamylyx.com
43 Thorndike Street
Cambridge, MA 02141
US
Cambridge, MA 02141
US
617 682 0917
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Latest News
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Consensus Rating of “Moderate Buy” from Analysts
437,391 Shares in Amylyx Pharmaceuticals, Inc. $AMLX Purchased by Ally Bridge Group NY LLC
Amylyx Pharmaceuticals, Inc. $AMLX Shares Acquired by Alpha Wave Global LP
HC Wainwright Brokers Increase Earnings Estimates for AMLX
Amylyx anticipates LUCIDITY trial results in Q3 2026 while advancing PBH market strategy
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Cohen Joshua B | A-Award | 248,865 | — | 2026-03-05 |
| Cohen Joshua B | A-Award | 373,295 | $14.10 | 2026-03-05 |
| Mazzariello Gina | A-Award | 74,660 | — | 2026-03-05 |
| Mazzariello Gina | A-Award | 111,990 | $14.10 | 2026-03-05 |
| FRATES JAMES M | A-Award | 95,990 | — | 2026-03-05 |